A webcast of the fireside chat will be accessible on MindMed's Investor Relations website starting on
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.
Contact:
Email: media@mindmed.co
Email: ir@mindmed.co
(C) 2024 Electronic News Publishing, source